Effect of initial pulmonary arterial hypertension-specific dual oral combination therapy on New York Heart Association functional class (NYHA FC), symptoms, exercise capacity, brain natriuretic peptide (BNP) and haemodynamics at first follow-up visit (n=97)
| Baseline | First follow-up visit# | p-value | |
| NYHA FC I/II/III/IV n | 0/15/70/12 | 4/57/31/5 | <0.001 |
| Clinical signs of RHF n (%) | 49 (51) | 25 (26) | <0.001 |
| 6-min walk distance m | 324±132 | 395±114 | <0.000 01 |
| Borg dyspnoea index | 4.3±2.0 | 3.1±1.9 | <0.000 01 |
| BNP¶ ng·L−1 median (IQR) | 372 (115–710) | 62 (34–274) | <0.000 01 |
| Haemodynamics | |||
| RAP mmHg | 9.5±5.7 | 6.7±4.5 | <0.000 01 |
| mPAP mmHg | 53.9±10.4 | 45.1±10.9 | <0.000 01 |
| PAWP mmHg | 8.8±3.5 | 8.7±3.3 | 0.82 |
| Cardiac output L·min−1 | 3.94±1.17 | 5.65±1.62 | <0.000 01 |
| Cardiac index L·min−1·m−2 | 2.14±0.51 | 3.13±0.79 | <0.000 01 |
| PVR dyn·s·cm−5 | 1021±357 | 565±252 | <0.000 01 |
| Mean BP mmHg | 97±18 | 87±13 | <0.000 01 |
| Heart rate beats per min | 85±15 | 81±12 | <0.011 |
| SvO2 % | 59±8 | 67±8 | <0.000 01 |
Data are presented as mean±sd unless otherwise stated. RHF: right heart failure; IQR: interquartile range; RAP: right atrial pressure; mPAP: mean pulmonary artery pressure; PAWP: pulmonary artery wedge pressure; PVR: pulmonary vascular resistance; BP: blood pressure; SvO2: mixed venous oxygen saturation. #: median follow-up time 4.1 months (IQR 3.5–4.9 months); ¶: n=42.